CRI’s 2017 Immunotherapy Patient Series Launches July 8 in San Francisco – Immuno-Oncology News
|
CRI’s 2017 Immunotherapy Patient Series Launches July 8 in San Francisco
Immuno-Oncology News Registration is now open for the 2017 Immunotherapy Patient Summit Series, a set of free half-day events in five U.S. cities focusing on immunotherapy and clinical trials, says the Cancer Research Institute (CRI). CRI held its first Immunotherapy … |
New Scientist |
CRISPR gene editing technique is probably safe, study confirms
New Scientist By Michael Le Page. As you were. In May, a study claimed that the revolutionary CRISPR gene editing technique can cause thousands of unwanted and potentially dangerous mutations. The authors called for regulators to reassess the safety of the technique. CRISPR’s high costs may limit development of gene therapy drugsGenetic Literacy Project |
Genetic Literacy Project |
CRISPR’s high costs may limit development of gene therapy drugs
Genetic Literacy Project “I’m not even sure that many of these gene therapies will work, and not all medicine is worth the price.” But if these technologies become broadly used, especially in altering T cells for cancer, payers won’t meet the demands of steep prices, and … |
The Sun |
What is immunotherapy, could Bradley Lowery be helped by the cancer treatment cost and how much does it cost?
The Sun A PIONEERING cancer treatment that “weaponises” the body’s immune system has been labelled as “breakthrough” in the fight against cancer. Immunotherapy targets defensive T-cells, and modifies them to seek out and destroy cancer, but how exactly does … Personalised vaccines to treat skin cancer show promise in small studiesCancer Research UK |
Friedreich’s Ataxia News |
Researchers Create ‘Heart Cells in a Dish’ to Study FA Heart Disease
Friedreich’s Ataxia News Australian researchers have successfully turned stem cells from Friedreich’s ataxia (FA) patients into heart cells to study molecular anomalies that may contribute to this disease. These “heart cells in a dish” provide valuable information for the … |
|
Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of …
Nasdaq “Shire is leveraging decades of scientific leadership in hemophilia to advance research in gene therapy for this community,” said Paul Monahan, M.D., Senior Medical Director, Gene Therapy, Shire. “Drawing from our rich heritage, Shire is well equipped … |